Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.37 | -$0.37 | -$0.37 |
Q2 2024 | 1 | -$0.35 | -$0.35 | -$0.35 |
Q3 2024 | 2 | -$0.30 | -$0.28 | -$0.29 |
Q1 2025 | 1 | -$0.28 | -$0.28 | -$0.28 |
Q2 2025 | 1 | -$0.28 | -$0.28 | -$0.28 |
Q3 2025 | 1 | -$0.30 | -$0.30 | -$0.30 |
Q4 2025 | 1 | -$0.29 | -$0.29 | -$0.29 |
Rallybio Corporation last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.26 earnings per share for the quarter, topping analysts' consensus estimates of $-0.36 by $0.1. The company had revenue of 299,000 for the quarter and had revenue of 0 for the year. Rallybio Corporation has generated $-2 earnings per share over the last year ($-1.84 diluted earnings per share) and currently has a price-to-earnings ratio of -0.57. Rallybio Corporation has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/07/2024 | Q3 2024 | -$0.36 | -$0.26 | 0.1 | $75,000 | $299,000 |
08/08/2024 | Q2 2024 | -$0.42 | -$0.37 | 0.05 | $166,667 | $299,000 |
05/09/2024 | Q1 2024 | -$0.50 | -$0.47 | 0.03 | $0 | |
03/12/2024 | Q4 2023 | -$0.44 | -$0.50 | -0.06 | $228,000 | |
11/09/2023 | Q3 2023 | -$0.51 | -$0.45 | 0.06 | $0 | |
08/08/2023 | Q2 2023 | -$0.48 | -$0.46 | 0.02 | $0 | |
05/09/2023 | Q1 2023 | -$0.50 | -$0.39 | 0.11 | $0 | |
03/06/2023 | Q4 2022 | -$0.63 | -$0.43 | 0.2 | $0 | |
11/07/2022 | Q3 2022 | -$0.54 | -$0.58 | -0.04 | $0 | |
08/08/2022 | Q2 2022 | -$0.61 | -$0.57 | 0.04 | $0 | |
05/10/2022 | Q1 2022 | -$0.48 | -$0.47 | 0.01 | $0 | |
03/15/2022 | Q4 2021 | -$0.39 | -$0.42 | -0.03 | $0 | |
11/10/2021 | Q3 2021 | -$0.89 | -$0.37 | 0.52 | $0 | |
09/09/2021 | Q2 2021 | -$2.80 | -$0.36 | 2.44 | $0 | |
03/30/2021 | Q1 2021 | -$0.60 | $0 | |||
12/30/2020 | Q4 2020 | -$0.47 | $0 | |||
09/29/2020 | Q3 2020 | -$0.32 | $0 | |||
06/29/2020 | Q2 2020 | -$0.22 | $0 | |||
03/30/2020 | Q1 2020 | -$0.17 | $0 |
Rallybio Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based off last year's report dates.
In the previous quarter, Rallybio Corporation (:RLYB) reported $-0.26 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.36 by $0.1.
The conference call for Rallybio Corporation's latest earnings report can be listened to online.
The conference call transcript for Rallybio Corporation's latest earnings report can be read online.
Rallybio Corporation (:RLYB) has a recorded net income of $0. Rallybio Corporation has generated $-1.84 earnings per share over the last four quarters.
Rallybio Corporation (:RLYB) has a price-to-earnings ratio of -0.57 and price/earnings-to-growth ratio is -0.05.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED